



Roche Investor Relations ASCO Planner 2017

Saturday, June 3

Session Title: Lung Cancer—Non-Small Cell Metastatic

Session Type: Poster Session

Date: Sat, June 3

Location: Hall A

Time: 8:00 AM – 11:30 AM

Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi, MD, PhD; Stephen V. Liu, MD

- **Abstract 9025** Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). **Poster Board #351**
- **Abstract 9064** Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). **Poster Board #390**
- **Abstract 9092** Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. **Poster Board #418**

Session Title: Gynecologic Cancer

Session Type: Poster Session

Date: Sat, June 3

Location: Hall A

Time: 1:15 PM – 4:45 PM

Speaker Name: Gini F. Fleming, MD, FASCO

- **Abstract 5585** Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). **Poster Board #407**

Sunday, June 4

Session Title: Breast Cancer—Metastatic

Session Type: Poster Discussion Session

Date: Sun, June 4

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Rebecca Alexandra Dent, MD

- **Abstract 1009** LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC). **Poster Board #1**
Additionally discussed at the Poster Discussion Session on Sunday, June 4, 2017, 4:45 PM - 6:00 PM, at Hall B1

Session Title: Pediatric Oncology

Session Type: Poster Session

Date: Sun, June 4

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Birgit Georger, MD

- **Abstract 10524** A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab). **Poster Board #281**
Additionally discussed at the Poster Discussion Session on Sunday, June 4, 2017, 11:30 AM - 12:45 AM, at S504

Session Title: "Check" This Out: The Step Beyond PD-1 Blockade

Session Type: Clinical Science Symposium

Date: Sun, June 4

Location: Hall D1

Time: 9:45 AM - 11:15 AM

Speaker Name: Howard A. Burris, MD, FASCO

- **10:24 AM - 10:36 AM**
Abstract 105 A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

Session Title: Plenary Session Including the Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sun, June 4

Location: Hall B1

Time: 1:00 PM - 4:00 PM

Chair and/or Co-Chairs: David C. Smith, MD, FACP, University of Michigan; Daniel F. Hayes, MD, FASCO, University of Michigan Comprehensive Cancer Center

Monday, June 5

Session Title: Genitourinary (Nonprostate) Cancer

Session Type: Oral Abstract Session

Date: Mon, June 5

Location: Arie Crown Theater

Time: 8:00 AM - 11:00 AM

Speaker Name: Michael B. Atkins, MD

- **9:24 AM – 9:36 AM**

Abstract 4505 IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Session Type: Poster Session

Date: Mon, June 5

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Ignacio Melero, MD, Full Prof

- **Abstract 2549** Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors. **Poster Board #41**

Session Title: Developmental Therapeutics—Immunotherapy

Session Type: Poster Session

Date: Mon, June 5

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Wilson H. Miller, MD, PhD; Ryan J. Sullivan, M.D.

- **Abstract 3057** Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. **Poster Board #152**

- **Abstract 3063** Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity. **Poster Board #158**

Session Title: Breast Cancer—Local/Regional/Adjuvant

Session Type: Oral Abstract Session

Date: Mon, June 5

Location: Hall D2

Time: 9:45 AM - 12:45 PM

Speaker Name: Gunter Von Minckwitz, MD, PhD

- **9:45 PM - 9:57 AM**

Abstract LBA500 APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).

Session Title: Developmental Therapeutics—Immunotherapy

Session Type: Oral Abstract Session

Date: Mon, June 5

Location: Hall D1

Time: 1:15 PM - 4:15 PM

Speaker Name: Josep Tabernero, MD, PhD

- **1:39 PM - 1:51 PM**

Abstract 3002 Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

Session Title: Health Services Research, Clinical Informatics, and Quality of Care

Session Type: Poster Session

Date: Mon, June 5

Location: Hall A

Time: 1:15 PM - 4:45 PM

Speaker Name: James Signorovitch, PhD

- **Abstract 6599** Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. health plan population. **Poster Board #421**

Tuesday, June 6

Session Title: Lung Cancer—Non-Small Cell Metastatic

Session Type: Oral Abstract Session

Date: Tue, June 6

Location: Hall D1

Time: 9:45 AM - 12:45 PM

Speaker Name: David R. Gandara, MD, FASCO; Jaafar Bennouna, MD; Alice Tsang Shaw, MD, PhD

- **9:57 AM – 10:09 AM**
Abstract 9001 Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.
- **10:57 AM – 10:09 AM**
Abstract 9004 Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo).
- **12:09 PM – 12:21 PM**
Abstract LBA9008 Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.